Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
To reiterate the following:
Clarification regarding trial of SNG001 in hospitalised COVID-19 patients
Southampton, UK - 21 July 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company which originated from research at the University of Southampton, issues clarification with respect to yesterday's announcement
§ The trial of SNG001 in hospitalised COVID-19 patients is a Phase II trial (as clearly stated in the announcements of 18 and 25 March). A Phase II trial is designed to test the efficacy of a drug and takes place before the drug is approved or able to be marketed.
§ The protocol was approved by both MHRA and HRA (as detailed in announcement of 18 March) and further details can be found in respect of the full study on the Company's website https://www.synairgen.com/investors/presentations
§ As per the announcement of yesterday, the Company will be working with the regulators and other key groups to progress this potential COVID-19 treatment as rapidly as possible. As with any drug undergoing clinical trials, Synairgen will require regulatory approval before SNG001 can be marketed on a commercial basis.
The Company will provide additional updates in due course and will continue with further analysis of the data from the trial.
- To me this means one thing and one thing only; Synairgen want to take SNG001 to market and our next RNS will be regarding this - COPD may form part of it but realistically this is the obvious focus for the company during these times.
I think that the lack of news can only indicate that there are discussions going on with large pharma companies. SNG will know the results of the COPD trial and they will also know that their COVID data is bulletproof.
They will be using this as a bargaining tactic to negotiate a deal with someone as the release of news will mean the SP will skyrocket leaving the buyer to pay an even bigger fortune for SNG.
At these levels, withholding any news, we could realistically see Synairgen sell for circa £1bn. Any release of news will 1x-4x the value someone will have to pay.
I wonder how people are going to view vaccines over treatments when articles like this are circulating
https://www.rt.com/news/496801-pharma-not-accountable-vaccine-effect/
I wonder how many stop losses have been triggered at 200!
Hopefully this pushes people into picking these up. Need news Monday or we are likely going to see 160p by next Friday. IMO.
I had an alert set at 200p but not selling anytime soon.
It also says the results were adjusted:
"These differences could have affected the outcome, although at a press conference today the company commented that the analysis was adjusted for baseline risk factors"
Neutral news
Some of you won’t remember but only a few weeks back 120p was a pipe dream and those who suggested 240p were shot down. We got the initial result, we have peer review and FDA approval to come ASAP then COPD results and I imagine a buy out before we even see home trial results. The largest Biopharma buy out of 2019 was circa 60bn ...
Guys,
This isn't one of your poxy get rich quick shares. Can the pump and dump crew stick to snake oil please as your muddying the waters turning SNG into a sham.
I've been holding since April and have been waiting for this week eagerly. The end goal is a buy out to the value of god knows what. If we wanted to make a few quid I could have flogged a dead horse on twitter.